-
Mashup Score: 0Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore - 2 year(s) ago
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke - 2 year(s) ago
Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Time course profile of adverse events with darolutamide in the #ARAMIS trial. @cgratzke @UniFreiburg joins @CaPsurvivorship @DanaFarber to discuss data presented at #ESMO21. #WatchNow on UroToday > https://t.co/qOch41WE67 https://t.co/mXkWZ3wpNn
-
-
Mashup Score: 0Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore - 3 year(s) ago
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Delayed deterioration in patient Quality of Life, the impact of darolutamide on local symptoms in the #ARAMIS trial. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber discussing his recent #AUA21 presentation. #WatchNow > https://t.co/7M2QAWdAkc @Bayer https://t.co/DD0YM632nV
-
-
Mashup Score: 3Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke - 3 year(s) ago
Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Time course profile of adverse events with darolutamide in the #ARAMIS trial. @cgratzke @UniFreiburg joins @CaPsurvivorship @DanaFarber to discuss data presented at #ESMO21. #WatchNow on UroToday > https://t.co/qOch41F3ez https://t.co/F0r5S26y5e
-
-
Mashup Score: 0Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore - 3 year(s) ago
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Delayed deterioration in patient Quality of Life, the impact of darolutamide on local symptoms in the #ARAMIS trial. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber discussing his recent #AUA21 presentation. #WatchNow > https://t.co/7M2QAWdAkc @Bayer https://t.co/YTAhfFQnai
-
-
Mashup Score: 6ESMO 2021: Time Course Profile of Adverse Events of Interest and Serious Adverse Events with Darolutamide in the ARAMIS Trial - 3 year(s) ago
ESMO 2021 adverse events with darolutamide in the ARAMIS phase 3 trial, adverse events from ARAMIS, timing of adverse events among patients in ARAMIS,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Time course profile of adverse events of interest and serious adverse events with darolutamide in the #ARAMIS trial. Presentation by @cgratzke @Uniklinik_Fr. #ESMO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/h7M2kVytBi @myESMO https://t.co/Zo3u2N4WbO
-
-
Mashup Score: 0NUBEQA® (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - 3 year(s) ago
Phase III ARAMIS trial, analysis of the Phase III ARAMIS trial presented at the 2021 AUA, NUBEQA plus androgen deprivation therapy (ADT), urinary and bowel symptoms in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Darolutamide (NUBEQA®) impact on local symptoms evaluated in men with non-metastatic castration-resistant #ProstateCancer #nmCRPC. #ReadNow details on UroToday > https://t.co/lkJF86FytC @NUBEQAUS #PressRelease #ARAMIS @Bayer https://t.co/KPsKNr6IJA
-
-
Mashup Score: 1Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore - 3 year(s) ago
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Delayed deterioration in patient Quality of Life, the impact of darolutamide on local symptoms in the #ARAMIS trial. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber discussing his recent #AUA21 presentation. #WatchNow > https://t.co/7M2QAWdAkc @Bayer https://t.co/W7QEk3etzS
-
-
Mashup Score: 1
EAU 2021 ARAMIS trial results, Darolutamide (DARO) is a structurally distinct androgen receptor inhibitor, DARO significantly prolonged metastasis-free survival and overall survival vs placebo in men with nmCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from PBO during the open-label period of the phase 3 #ARAMIS study. Presentation by Susan Feyerabend. #EAU21 written coverage by @tchandra_uromd > https://t.co/ZyxVRy7AVM @Uroweb https://t.co/vtKXydkoSU
-
-
Mashup Score: 1
EAU 2021 Darolutamide (DARO) is a structurally distinct androgen receptor inhibitor, Men with nmCRPC are generally asymptomatic from their cancer, Criteria for Adverse Events (CTCAE).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Hormone treatment-related adverse events (HTR AEs) with darolutamide in Pts with #nmCRPC from the phase 3 #ARAMIS study. Presentation by Karim Fizazi, MD, PhD @GustaveRoussy. #EAU21 written coverage by @tchandra_uromd @KimmelCancerCtr > https://t.co/oJ7cA8Rq1a @Uroweb https://t.co/8DS9qAZzsx
-
Delayed deterioration in patient Quality of Life, the impact of darolutamide on local symptoms in the #ARAMIS trial. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber discussing his recent #AUA21 presentation. #WatchNow > https://t.co/7M2QAWdAkc @Bayer https://t.co/dNTu2wZKaB